Construction starts for Sartorius' new Cell Culture Technology Centre
Ground-breaking ceremony for Sartorius Stedim Cellca.
The 30-million-euro investment will accommodate the growing needs of customers.
Sartorius Stedim Cellca is building a new 30-million-euro Cell Culture Technology Center at Science Park III in Eselsberg situated at the northwestern scientific hub of the city of Ulm, Germany. Hugo de Wit, Managing Director, and Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius AG, symbolically broke ground in the presence of around 100 guests, marking the official start of construction work. “This is a significant step for Sartorius Stedim Cellca and our staff to soon be able to work in an advanced new complex. We are very proud of this as the new, modern facility will enable us to continue accommodating the growing needs of our customers in the future as well,” said de Wit.
So far, Sartorius Stedim Cellca has been working in a rented building in Laupheim. The new laboratory and office complex will approximately double the company’s space and is scheduled to be completed by the end of 2019. In addition, relocation to this zone will provide closer proximity to universities and research institutes that are based in Ulm’s Science Park. In addition, this move to the new facility, which is conveniently accessible by various transportation routes between the large cities of Stuttgart and Munich, will make it even easier for international customers to visit the company. Sartorius Stedim Cellca purchased the property of more than 6,000 m2 at Science Park III back in November 2016 and can, therefore, expand its Cell Culture Technology Center by a further 5,000 m2 as needed.
Sartorius Stedim Cellca develops cell lines and protein production processes, licenses technologies for the production of proteins and offers cell culture media. The company has been a part of the biopharma equipment supplier Sartorius Stedim Biotech since 2015 and currently employs around 90 people. Over the medium term, the company plans to extend its workforce to more than 120 people.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
.png)
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.